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Embryonic stem cells, cancer and genomic 
regulation
Embryonic stem (ES) cells are cultured cells derived from 
the inner cell mass of the blastocyst-stage embryo [1,2]. 
They exhibit two distinct properties: self-renewal, the 
ability to maintain a proliferative state without changes in 
cellular characteristics; and pluripotency, the capacity to 
generate all of the cell types of adult organisms. Under-
standing how these properties are established and main-
tained is crucial to realizing the full potential of ES cells 
in basic biology and regenerative medicine.
Previously, a small cadre of transcription factors, 
includ ing the homeodomain protein Oct4 (Pou5f1), SRY 
box-containing factor Sox2, and Nanog, were identified 
as key regulatory factors (or ES cell core factors) in 
control ling ES cell pluripotency [3-6]. Remarkably, 
Yamanaka and colleagues [7,8] observed that somatic 
cells can be reprogrammed into ES cell-like cells (induced 
pluripotent stem (iPS) cells) by the introduction of four 
transcription factors: Oct4, Sox2, Klf4, and Myc [7-11]. 
This observation clearly underscores the relevance of 
transcriptional regulatory mechanisms to pluripotency 
and cell fate control [12].
During the past decade, advances in high-throughput 
technologies, such as gene expression profiling, the 
global mapping of transcription factor-DNA interactions 
and histone modifications by microarrays or sequencing 
(chromatin immunoprecipitation (ChIP)-chip or ChIP-
sequencing) [13], the mapping of protein-protein inter-
actions, the identification of members of protein 
complexes by affinity purification followed by mass 
spectrometry (MS) [14], and the unbiased knockdown of 
genes by RNA interference (RNAi) [15], have facilitated 
the assembly of considerable databases of proteomic and 
genomic information. These new tools provide the basis 
for the development of a comprehensive understanding 
of cell states at the systems level and have been applied to 
dissect self-renewal and pluripotency control in ES cells, 
reprogramming processes, and lineage specification 
[16,17].
In the context of cancer biology, an important goal has 
been delineation of the cells that sustain cancers. Investi-
gators have suggested that a small population of cells 
within a tumor may reinitiate tumor formation upon 
trans plantation and be responsible for the maintenance 
of tumors and their resistance against effective 
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anti-cancer therapy. Such cancer stem cells, or more 
precisely tumor initiating cells, might arise from adult 
stem, or progenitor, cells or from the dedifferentiation of 
somatic cells [18]. It has been hypothesized that the 
similarities shared by stem cells and cancer cells might 
relate to shared patterns of gene expression regulation, 
which might be associated with the ‘embryonic’ state. 
Moreover, recent studies focusing on somatic cell re-
programming underscore the similarity between cancer 
cells and iPS cells. The acquisition of pluripotency during 
the reprogramming process is superficially reminiscent 
of the dedifferentiation proposed for some cancers [19]. 
In trying to account for the self-renewing properties of 
cancer stem cells, several investigators have defined ‘ES-
cell-specific expression’ signatures, and these have been 
analyzed in diverse cancers [20-26].
In this review, we provide an overview of the current 
understanding of the ES-cell-specific gene expression 
programs that have been observed in various human 
cancers. We first summarize the key regulatory factors 
involved in controlling the self-renewal and pluripotency 
of ES cells, which have been thoroughly evaluated using 
various systems biology tools. We then discuss how these 
factors have contributed to our understanding of the 
gene expression signatures that are shared between ES 
cells and cancer cells. Finally, we discuss the implications 
of these observations for medicine.
Regulatory factors in self-renewal and 
pluripotency
In this section, we provide a brief overview of the key 
factors that regulate the self-renewal and pluripotency of 
ES cells, and the acquisition of pluripotency during somatic 
cell reprogramming. Recently, genome-scale technologies 
and systems-level approaches have been widely applied 
to investigate regulatory mechanisms in ES and iPS cells. 
The key regulators in pluripotent stem cells, their func-
tions, and the experimental methods applied to investi-
gate them are summarized in Table 1.
Core transcription factors
Initially, a few transcription factors that are critical to ES 
cell pluripotency, core factors Oct4, Sox2, and Nanog, 
were identified and functionally characterized by low-
throughput methods [3-6]. Subsequently, global targets 
of these core factors have been identified in mouse ES 
cells using ChIP combined with paired-end-tag-based 
sequencing methods (ChIP-PET) [27] and in human ES 
cells using ChIP-chip [28]. The results suggested that 
each of the key transcription factors has numerous 
(>1,000) chromosomal targets, and that the factors are 
auto-regulated and subject to cross-regulation in an inter-
connected network. A Nanog-centered map of protein-
protein interactions in ES cells has also been constructed 
using affinity purification followed by MS [29]. With the 
addition of the more recent Oct4-centered protein-
protein interaction maps [30,31], these approaches 
expanded the initial ES cell core network by identifying 
novel interacting partners of the core factors. Using a 
ChIP-based method, subsequent mapping of chromo-
somal targets of the nine transcription factors within this 
expanded core network (that is, three core factors, Nanog-
interacting proteins, and Yamanaka’s four somatic-cell-
reprogramming factors) revealed a positive correlation 
between transcription factor co-occupancy and target 
gene activity [32]. These results also provided an initial 
Table 1. Genome-scale studies of self-renewal and 
pluripotency in ES cells
Regulators Function Methods Reference(s)
Core factors   
Oct4 (Pou5f1) ES cell core factor ChIP, MS [27-32,44]
Sox2 ES cell core factor ChIP, MS [28,32,44]
Nanog ES cell core factor ChIP, MS [27-29,32,44]
Tcf3 (Tcf7l1) Wnt signaling ChIP [74]
Klf4 LIF signaling ChIP [32,44]
Stat3 LIF signaling ChIP [44]
Dax1 (Nr0b1) Negative regulation of  ChIP, MS [29,32] 
 transcription
Sall4 Self-renewal and  ChIP, MS [29,75-77] 
 pluripotency
Polycomb-related factors   
Ezh2 PRC2, repressor ChIP, MS [78,79]
Jarid2 Fine-tuning of PRC2 ChIP, MS [78,79]
Mtf2 Polycomb-like protein ChIP, MS [78]
Suz12 PRC2, repressor ChIP, MS [37,38,78,79]
Eed PRC2, repressor ChIP [37,38]
Rnf2 PRC1, repressor ChIP [37]
Phc1 PRC1, repressor ChIP [37]
Myc-related factors   
Myc Proliferation ChIP, MS [20,44]
Max Myc-interacting  ChIP, MS [20]
Zfx Self-renewal ChIP [44]
Trrap Histone acetylation RNAi [50]
Tip60 (Kat5) Histone acetylation ChIP, MS, RNAi [20,50]
Ep400 Histone acetylation MS, RNAi [50]
Dmap1 Histone acetylation ChIP, MS, RNAi [20,50]
E2F1 Regulator of cell cycle ChIP [44]
E2F4 Transcription activator ChIP, MS [20]
Cnot3 General transcription  ChIP, RNAi [80] 
 regulator
Trim28 (Tif1b) Transcription co-activator ChIP, RNAi [80]
LIF, leukemia inhibitory factor.
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glimpse into the unique roles of Myc in ES cells and 
somatic cell reprogramming. Myc has more target genes 
than any of the core factors, and its target genes show 
unique histone modification marks in their promoters.
Somatic cell reprogramming by defined factors
In the first report of somatic cell reprogramming by 
Yamanaka’s group, mouse fibroblasts, which represent 
terminally differentiated cells, were reprogrammed to 
become pluripotent-stem-cell-like cells (iPS cells) by the 
introduction of four transcription factors: two core ES 
cell factors (Oct4 and Sox2), Klf4 and c-Myc (Myc) [7]. 
Successful reprogramming of human fibroblasts to iPS 
cells [8,10,11], together with the generation of disease-
specific iPS cell lines using the cells of people with genetic 
disorders, provides a basis for in vitro culture-based 
studies of human disease phenotypes [33,34]. Notably, as 
shown by Yamanaka’s initial work, the four reprogram-
ming factors are highly expressed in ES cells. Additionally, 
these reprogramming factors are implicated in tumori-
genesis in diverse cancer contexts [19,35]. These observa-
tions raise the hypothesis that somatic cell reprogram-
ming, pluripotency control in ES cells, and cellular 
transformation might share common pathways.
Polycomb-related factors
Polycomb-group (PcG) proteins, which were first 
discovered in fruit flies, contribute to the repressed state 
of crucial developmental or lineage-specific regulators by 
generating a repressive histone mark. PcG proteins have 
essential roles in early development, as well as in ES cells 
[36]. Mapping of the targets of PcG-repressive protein 
complex (PRC)1 and PRC2 in mouse and human ES cells 
by ChIP-chip showed that PRC proteins occupy many 
common repressed target genes, including lineage-specific 
transcription factors [37,38]. These studies suggest that 
PRC proteins serve to maintain the undifferentiated state 
of ES cells by repressing important developmental regula-
tors. Recent experiments involving RNA immuno preci pi-
tation followed by sequencing (RIP-sequencing) impli-
cate the interaction of various non-coding RNA molecules 
with the PRC complex in the regulation of target genes 
[39]. PRC proteins are also implicated in the somatic cell 
reprogramming process [40,41].
Myc and Myc-interacting factors
Activation of Myc, one of the most-studied oncogenes, is 
reported in up to 70% of human cancers [42]. Myc has 
numerous cellular functions and is involved in many 
biological pathways, including the control of self-renewal 
in ES cells [43]. Mapping of Myc targets in ES cells has 
suggested that Myc’s role in maintaining the pluripotency 
of ES cells is distinct from that of the core factors [32,44]. 
Myc has many more chromatin targets than the core ES 
factors, and Myc target genes are enriched in pathways 
that are associated with metabolism and protein syn-
thesis. By contrast, the targets of the core factors are 
involved in transcription and developmental processes 
[32,44]. In the context of somatic cell reprogramming, 
Myc is a dispensable factor [45,46]; but efficient and rapid 
reprogramming by Myc suggests that this factor might 
generate a favorable environment during the reprogram-
ming process, potentially by mediating the global 
alteration of chromosome structure [47-49]. Recently, 
Myc-interacting partner proteins and their genomic 
targets have been identified in ES cells [20]. These studies 
revealed that the Myc network is distinct from the ES cell 
core interaction network or the PRC network. Interest-
ingly, an independent RNAi-based knockdown screen 
showed that Tip60-p400 histone acetyltransferase (HAT) 
complex proteins, which interact with Myc in ES cells 
[20], also play a crucial role in ES cell identity [50], 
implicating the functions of Myc-interacting proteins in 
the control of ES cell pluripotency and somatic cell 
reprogramming.
Common signatures in ES cells and cancer
Overlapping characteristics that are shared by ES cells 
and cancer cells have led investigators to examine the 
gene expression patterns that underlie these similarities 
[18]. We now know that one of the factors used to facili-
tate somatic cell reprogramming, Myc, is an estab lished 
oncogene, and that the inactivation of p53 pathways, as 
observed in innumerable cancers, increases the efficiency 
of the reprogramming process [7,51-54]. These dis-
coveries provide additional evidence that common 
pathways could be utilized both in the acquisition of 
pluripotency and in tumorigenesis. In this regard, data 
generated from various systems biology tools that can be 
used to dissect ES cell pluripotency and somatic cell 
reprogramming could play a crucial role in identifying 
the common features shared by ES cells and cancer cells. 
In turn, many ES-cell-specific gene sets, modules, or 
signatures that have been identified by systems biology 
studies of pluripotent stem cells have provided useful 
analytical tools for analyses of the gene-expression 
programs of human tumors and mouse tumor models. 
Recent analyses of ES-cell-specific signatures in human 
tumors are summarized in Table 2.
ES cell signatures tested in cancer
In one of the first studies aimed at revealing shared gene 
expression patterns, Chang and associates [22] collected 
large-scale data sets that had been acquired from ES cells 
or adult stem cells, and constructed a gene-module map. 
From the initial gene-module map, two modules (gene 
sets) that distinguish ES cells (the ESC-like module) and 
adult stem cells (the adult tissue stem cell module) were 
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defined. The activities of these two modules were tested 
using gene expression data sets from various human 
tumor samples (Table  2). Chang’s group observed that 
the ESC-like module is activated in various human 
epithelial cancers. Moreover, they showed that Myc 
activates the ESC-like module in epithelial cells. Taking 
these observations together, the group proposed that the 
activation of an ES-cell-like transcriptional program via 
Myc might induce the characteristics of cancer stem cells 
in differentiated adult cells. Independently, Weinberg and 
colleagues [23] defined 13 gene sets in ES cells from 
previously existing large-scale data sets and placed each 
of these 13 data sets into one of four categories: ES-
expressed, active core factor (Nanog, Oct4, and Sox2) 
targets, PRC targets, and Myc targets. When these data 
sets were tested using expression profiling data sets from 
human cancer patients, the activation of ES-cell-specific 
gene sets (such as ES-expressed) and the repression of 
PRC target genes were significantly enriched in poorly 
differentiated human tumors. A similar approach defined 
a consensus stemness ranking (CSR) signature from four 
different stem cell signatures, and also showed that the 
CSR signature has prognostic power in several human 
cancer types [24]. Notably, an active ES-cell-like expres-
sion program has been observed upon inactivation of p53 
in breast and lung cancers [25]. Similar to the function of 
p53 in the acquisition of pluripotency during reprogram-
ming, the inhibition of p53 or the p53 pathway increases 
the efficiency of somatic cell reprogramming [53]. Taken 
together, these studies clearly show that ES-cell-specific 
signatures are shared among various human cancers and 
animal cancer models; but the precise nature of the gene 
expression pathways remains unclear.
Predominant ES cell Myc module in cancer
Although ES cells and cancer cells share some properties, 
cancer cells do not exhibit true pluripotency like that 
displayed by ES cells. Furthermore, early studies failed to 
establish that the crucial ES-cell pluripotency genes were 
actually expressed in cancer cells and could account for 
the apparent similarities between ES cells and cancer 
cells [55,56]. So how specific are the proposed ES-cell-
specific gene modules? Recent findings lead to a more 
nuanced view of the relationship between ES cells and 
cancer cells. A Myc-centered regulatory network was 
first constructed in ES cells by combining the data sets 
acquired from a MS-based proteomics method as well as 
a ChIP-based method. When this Myc-centered regula-
tory network was combined with previously defined ES 
cell pluripotency, core and PRC networks, it was shown 
that the transcription regulatory program that controls 
ES cells can be subdivided into functionally separable 
regulatory units: core, PRC and Myc [20]. Such ES cell 
modules were defined on the basis of the target co-
occupancy of the factors within the regulatory units. 
Subsequently, the averaged activity of the three modules 
(common target genes within each regulatory unit - core, 
PRC and Myc modules) was tested in ES cells and in 
various cancer types. In ES cells, the core and Myc 
modules are active, but the PRC module is repressed. An 
active Myc module is observed in many cancer types and 
generally predicts poor prognosis. On the other hand, the 
core module, which is highly active in ES cells and 
underlies the ES cell state, is not significantly enriched in 
most cancers. In contrast to the previous studies, this 
work suggests that the similar expression signatures of ES 
cells and cancer cells largely reflect the contribution of 
the Myc regulatory network rather than that of an ES-
cell-specific core network. This conclusion is in accor-
dance with the previous observation that Myc induces an 
ESC-like module in epithelial cells [22]. Note also that 
many genes in the previously defined ESC-like modules 
proposed by others [22,23] are direct target genes of Myc 
and are therefore likely to reinforce the common 
signature.
Repressive targets of PRC2 in cancer
PRC complexes (especially PRC2 proteins, including 
Ezh2, Eed, and Suz12) are important repressors of gene 
regulation that are highly expressed in ES cells. Their 
Table 2. Studies of embryonic stem cell signatures in cancer
Study Gene sets used in the study Gene set generated by: Tested cancers
Ben-Porath et al. [23] ES cell expression profiles, Nanog, Oct4,  ES-cell-specific gene expression,  Breast, glioma, and bladder cancers
 Sox2 targets, Myc targets, and PRC targets and factor occupancy 
Wong et al. [22] ES-cell-like module, adult stem cell module Gene module map [81] Liver, breast, prostate, gastric, and lung cancers
Schoenhals et al. [26] Nanog, Oct4, Sox2, and Klf4 ES-cell-specific gene activity in  Multiple cancers
  multiple cancers
Kim et al. [20] Core module, PRC module, and Myc  Factor co-occupancy within Myeloid/lymphoid leukemia, bladder and
 module transcription sub-networks breast cancers
Mizuno et al. [25] ES cell, iPS cell, PRC2, and p53 ES cell  Gene expression profiles Breast cancer
 signatures
Shats et al. [24] CSR signature Combined gene sets Breast and lung cancers, adenocarcinoma, and 
   medulloblastoma
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down stream targets, including many lineage-specific 
regulators, are repressed or inactive in ES cells [37,38]. 
Weinberg and associates [23] observed that the target 
genes of PRC are also repressed in various human 
cancers, and that the repression of PRC target genes also 
predicts poorly differentiated human tumors. Interest-
ingly, overexpression of PRC2 proteins is often observed 
in many different cancers; for example, Ezh2, a catalytic 
subunit of PRC2, has been reported to be a marker for 
aggressive prostate and breast tumors [57,58]. In our 
study of modules within ES cells, we also observed that 
repression of target genes by PRC is shared between ES 
cells and cancer cells [20]. These results strongly suggest 
that, in addition to the Myc network, a PRC network also 
generates expression signatures that are shared by ES 
cells and cancer cells.
ES cell core factors in cancer
Do ES cell core factors ever play a crucial role in cancer? 
For those cancers of germ cell origin, the expression of 
ES-cell-specific pluripotency factors, such as Oct4 and 
Nanog, is likely to be functionally relevant [59]. It has 
been reported that transcripts of Oct4, Nanog, and/or 
Sox2 may be expressed in epithelial cancers, and that 
their expression is correlated with tumor grade 
[26,60,61]. Nevertheless, the subject remains contro ver-
sial because the expression of pseudogenes for Oct4 has 
confounded studies based on RNA expression alone 
[62,63]. Another key factor in ES cells, Sox2, was 
implicated in lung and esophageal squamous cell carci-
no mas; but the induction of Sox2 in a lung adeno-
carcinoma cell line promoted squamous traits rather 
than pluripotency-related characteristics. This suggests a 
role for Sox2 as a lineage-survival oncogene rather than 
as a stemness marker [60]. Our recent work has shown 
that the core module, which relates to ES cell core factors, 
is not significantly enriched in human epithelial tumors 
[20]. Thus, the contribution of ES-cell-specific core factors 
to tumor formation or maintenance is still uncertain.
Implications for cancer and medicine
The extent to which the study of pluripotent ES cells has 
provided insights into cancer is remarkable. In addition, 
the involvement of both oncogenic and tumor suppressor 
pathways in somatic cell reprogramming suggests that 
continued study of the relationship between ES cells and 
cancer cells is worthwhile. In this section, we discuss how 
ES cells might be used to accelerate the translation of 
basic findings into clinically relevant tests and new 
therapeutic approaches.
Classically, cancer cell lines have been employed as 
convenient biological models when investigating the 
characteristics of various cancers and as a platform for 
exploring the activity of chemotherapeutic agents. Cell 
lines are not usually a preferred platform for drug 
screening because they often represent highly selected 
subpopulations of cancer cells, with accumulated genetic 
mutations or abnormalities acquired during long-term 
culture. The shared signatures of ES cells and cancer cells 
suggest, however, that ES cells could provide an alter-
native system for studying pathways relevant to cancers. 
One strategy is depicted in Figure 1. In this scenario, 
genetic and/or chemical modulators that negate or alter 
the activities of signatures that are shared by ES cells and 
cancer cells may be sought in ES cells by high-throughput 
screening. Subsequently, selected modulators could then 
be re-validated in cancer cells either in culture or in 
various transplant protocols. A variation of this theme is 
the recent application of gene expression signatures to 
identify drugs that target specific signaling pathways 
(such as those for Ras, Src, and Myc) [64-66].
A particularly powerful approach is now afforded by an 
elegant in silico method based on the ‘Connectivity Map’ 
[67,68]. The Connectivity Map encompasses an expand-
ing database of gene expression profiles from a collection 
of reference cell lines treated with ‘perturbagens’ [69]. In 
the original version of the Connectivity Map, cells were 
treated with numerous drugs, but the approach is entirely 
general and cells may be ‘perturbed’ by any chemical or 
genetic manipulation. In practice, the Connectivity Map 
database is interrogated with a gene expression signature 
of interest to ask whether the signature resembles the 
action of a perturbagen on the reference cells. As the 
method is performed in silico, it is extremely rapid.
An initial attempt to identify drugs that modulate an 
ES-cell-like gene expression signature has already been 
reported. In this instance, the Connectivity Map database 
was interrogated with an ES-cell signature, described as a 
CSR [24], to predict drugs that affect the CSR signature. 
Putative ‘hits’ were subsequently validated in human 
breast cancer cells. The results revealed multiple topo iso-
merase inhibitors, including daunorubicin, that decrease 
cell viability in this context [24]. We anticipate that 
further interrogation of the Connectivity Map data base 
with other expression signatures could highlight agents 
that form the basis for novel therapeutic approaches.
Conclusions and future directions
In recent years, the utilization of emerging systems 
biology techniques in stem cell biology have led to 
considerable advances in our understanding of the 
regula tory networks that control the pluripotency of ES 
cells and the process of somatic cell reprogramming. We 
began with just a handful of core ES cell transcription 
factors, but now appreciate a more extensive list of 
transcription factors that are involved in the regulation of 
these processes. Cross-examination of large data sets 
generated by various tools, taken together with 
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computational analysis, has led to an improved under-
standing of the gene-expression patterns that are 
common to ES and cancer cells. Rather than identifying 
core ES cell factors as contributors to shared patterns, the 
recent studies underscore sub-modules that refer to Myc 
and Polycomb transcriptional activities.
An improved understanding of the features shared by 
pluripotent cells and cancer cells is of potential clinical 
relevance. In the future, the common pathways could 
serve as putative targets for anti-cancer drugs, but 
unresolved questions remain. Recent studies describe 
overlapping expression signatures that are shared by ES 
cells and various human cancers and that also predict 
patient outcome, but more careful analysis needs to be 
performed to reveal the multiple contributions to these 
signatures. The heterogeneity of cancers presents a 
challenge to the field. Many different cell types reside 
within a given tumor, and tumors differ from one to 
another, but current methods deal poorly with cellular 
heterogeneity. The extent to which core ES cell 
pluripotency factors are involved in epithelial cancers, or 
in a subset of cancer stem cells, remains to be explored. If 
they are expressed, it is relevant to ask whether the genes 
or gene pathways that are controlled by ES cell core 
factors in cancer cells are similar to those regulated by 
these core factors in pluripotent stem cells.
Moreover, additional layers of regulatory mechanisms 
that await further characterization might be shared 
between ES cells and cancers. For example, microRNAs, 
which are crucial regulators of the pluripotent state and 
cell proliferation [70,71], might have patterns of regula-
tion and downstream target genes that are common to ES 
and cancers cells. An improved understanding of signal-
ing pathways that are implicated in both ES cells and 
cancer (or cancer stem cells) [72,73], and their connec-
tions to the regulatory networks, is also of special 
interest. Finally, it will be instructive to determine 
whether chemicals or genetic modulators could change 
or shift the activity of common signatures or modules 
shared between ES and cancer cells. The opportunities 
provided by these approaches could accelerate the 
identification and development of new cancer therapies.
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Figure 1. Schematic representation of signatures that are common to ES cells and cancer cells. An activated Myc module (involving Max, Myc 
and NuA4; red arrow) and a repressed PRC module (involving PRC1 and PRC2; blue arrow) have been suggested as signatures that are common 
to ES cells and cancer cells. An activated core module (involving Oct4 and Nanog) is specific to ES cells. Genetic and/or chemical modulators that 
can change or shift the activity of these shared modules can be identified by high-throughput screening in ES cells, and the identified modulators 
might also alter the activity of the shared signatures in cancer cells.
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